CapsoVision, Inc.
$8.9M 776 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Astellas Pharma Global Development
Astellas Pharma Global Development reported $8,896,746.83 across General Payments, Research, and Ownership to 866 physicians and teaching hospitals across 3,122 transactions.
- $8.9M Top 10% payer
- All-tracks total
- 3,122 Top quartile volume
- Transactions
- 866 Above-median reach
- Recipients
- +$277.4K
- General Payments vs PY2023
Astellas Pharma Global Development reported $8,896,746.83 across all CMS Open Payments tracks (General + Research + Ownership) to 866 physicians and teaching hospitals in Program Year 2024 - ranking #190 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $662,038.58, averaging $10.3K per recipient.
How Astellas Pharma Global Development's $8.9M all-tracks total breaks down
Astellas Pharma Global Development's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
48/100
Total payments
A
92/100
Transaction volume
F
33/100
Physician reach
F
17/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer astellas-pharma-global-development Astellas Pharma Global Development
$8.9M · #190/1,925 · 0.1% industry · PY2024
- TOT $8.9M
- RANK #190
- SHARE 0.1%
- TXN 3,122
- RCP 866
- CAT 4
- GEN $662.0K
- ΔGEN +$277.4K
- TOP1 11.3%
- PY 2024
Volume peers
Nearest volume peer: CapsoVision, Inc. ($8.9M)
Astellas Pharma Global Development sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Astellas Pharma Global Development's CMS-reported General Payments increased by $277.4K (+72.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ASTELLAS PHARMA GLOBAL DEVELOPMENTPY2023: ASTELLAS PHARMA GLOBAL DEVELOPMENTPY2024: Astellas Pharma Global Development. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $384,593.79
- PY2024
- $662,038.58
What the Data Shows for Astellas Pharma Global Development
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Astellas Pharma Global Development, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
158 transactions worth $598.6K make "Consulting Fee" the top general-payment category in the 4-category breakdown below, 90.4% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Astellas Pharma Global Development's 4-category general-payment breakdown at $598.6K, 90.4% of the reported total.
Astellas Pharma Global Development reports 4 general-payment categories - the top three are Consulting Fee (90.4%), Food and Beverage (7.0%), and Travel and Lodging (2.6%). The remaining 1 category make up 0.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Astellas Pharma Global Development divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $598.6K | 158 | 90.4% |
| Food and Beverage | $46.2K | 659 | 7.0% |
| Travel and Lodging | $16.9K | 44 | 2.6% |
| Education | $266.00 | 5 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $245,827.92 (37.1%) of $662,038.58 in this company's General Payments records across 637 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Astellas Pharma Global Development
The five named recipients with the highest reported General Payments from this company
- 1
National Jewish Health
$75,000.00 across 1 reported transactions
- 2
Rush University Medical Center
$70,000.00 across 1 reported transactions
- 3
Dilraj S Grewal
$35,927.92 across 9 reported transactions
- 4
Eleonora Lad
$35,850.00 across 9 reported transactions
- 5
Michael Allingham
$29,050.00 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Astellas Pharma Global Development ranks #190 of 1,925 by total payments (top 10% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,382 of 1,838 by HHI (bottom 25% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Shionogi Inc : $1.4M total payments, HHI 403
- ALK-Abello, Inc : $339.4K total payments, HHI 403
- Verity Pharmaceuticals Inc. : $293.4K total payments, HHI 398
- Biocon Biologics Inc : $26.5K total payments, HHI 391
- Phadia US Inc. : $290.0K total payments, HHI 390
- Sonendo Inc : $1.3M total payments, HHI 386
- Astellas Pharma Global Development (this company) : $662.0K total payments, HHI 386
- Breg, Inc : $959.96 total payments, HHI 385
- Impulse Dynamics (USA) Inc. : $1.3M total payments, HHI 385
- Medela LLC : $63.1K total payments, HHI 384
- Ovesco Endoscopy USA, Inc. : $61.0K total payments, HHI 384
- Augmedics Inc. : $233.7K total payments, HHI 383
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Astellas Pharma Global Development's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Astellas Pharma Global Development.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Astellas Pharma Global Development.
Showing 6 of 1,924 companies with CMS-reported payment data.
Si-Bone, Inc.
$8.9M 13,924 recipients
Compare payment profiles
4WEB, Inc.
$8.9M 718 recipients
Compare payment profiles
SpectraWAVE, Inc
$8.7M 181 recipients
Compare payment profiles
Tyber Medical, LLC
$9.1M 27 recipients
Compare payment profiles
Tarsus Pharmaceuticals, Inc.
$9.1M 33,978 recipients
Compare payment profiles
Put this to use
Astellas Pharma Global Development ranks #190 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Astellas Pharma Global Development sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Astellas Pharma Global Development. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.